NOV
Novo Nordisk A/S Class B · BX:NOV
32.66 CHF0.4470 +1.39%
Novo Nordisk A/S Class B (BX:NOV) last traded at 32.66 CHF, up 1.39% on the day. Over the past year the stock is down 20.75%. Its 52-week range is 27.84 to 50.84. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open32.55
Day range32.52 – 32.70
52-week range27.84 – 50.84
Volume1.71 K
Average volume (10 days)872
Market cap (USD)175.64 B
P/E10.12
EPS (TTM) (USD)3.99
Dividend yield4.40%
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+0.11%1 week
+2.89%1 month
−20.06%3 months
+2.91%6 months
−21.43%Year to date
−20.75%1 year
Technical rating
Neutral
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
37.76 CHF
The average 1-year price target, +15.62% from the last price. See the forecast
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.